الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 136 |  |  |
| | | from | 136 | | |
Abstract
This study aimed to detect T315I mutation in chronic myeloid leukemia patients, and to evaluate its relation to TKIS resistance. Patients divided into 2 groups:group A: CML patient resistant to TKI and group B: CML patient responder to TKI the sample size was Convenient sample of 100 patients sample. All subjects were undergo Clinical examination. Routine lab testing including: complete blood count, liver function test, kidney function test, peripheral blood smear if available, Bone marrow aspirate and/or biopsy BCR-ABL Fusion gene by RT-PCR and Specific teat. We used AS-PCR to detect T315I mutation in chronic myeloid leukemia patients, and evaluated its relation to TKIS resistance. We found that 30% of patient who were resistant to TKI were T315I positive where none of the responders showed any positive mutation for T315I.Additionally, BCR-ABL transcript was higher in positive T315I cases at all time points. We also noticed that patients who are CML resistant to TKI had significantly higher frequency of hepatomegaly as well as higher TLC when compared to responder group. Otherwise, laboratory data did not differ significantly between studied CML groups, also Sokal risk score did not differ significantly between TKI sensitive and resistant CML groups. While higher Hasford risk score was significantly associated with resistant group In addition, there were significantly higher BCR-ABL transcripts at 0, 3, 6, 12, and 18 months in the CML resistant cases when compared to sensitive cases.